Records containing: Schizophrenia

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2016-11-08
  A 6-month, Randomised, Double-blind, Parallel-group, Risperidone-controlled, Fixed-dose Study Evaluating the Safety and Efficacy of Zicronapine in Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2016-11-03
  Recovery After an Initial Schizophrenia Episode (RAISE): The RAISE Connection Program Duration of Untreated Psychosis (DUP)
• CLINICAL_TRIALS study record update · 2016-11-02
  A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
• CLINICAL_TRIALS study record update · 2016-11-02
  Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
• CLINICAL_TRIALS study record update · 2016-11-02
  tDCS & Auditory Hallucinations in Schizophrenia (AVH-SZ)
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2016-11-02
  A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness
• CLINICAL_TRIALS study record update · 2016-11-02
  A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Schizophrenia and Schizoaffective Disorder
• CLINICAL_TRIALS study record update · 2016-11-02
  A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia
• CLINICAL_TRIALS study record update · 2016-11-02
  A Prospective, Non-Interventional Registry of Diverse Patients With Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of Disease, Treatments, and Burden of Illness
• CLINICAL_TRIALS study record update · 2016-11-02
  Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.
• CLINICAL_TRIALS study record update · 2016-11-02
  A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography
• CLINICAL_TRIALS study record update · 2016-11-02
  ClinicalTrials.gov study NCT01959659
• CLINICAL_TRIALS study record update · 2016-11-02
  A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE.
• CLINICAL_TRIALS study record update · 2016-10-31
  Effects of CBT and Cognitive Remediation on Work in Schizophrenia
• CLINICAL_TRIALS study record update · 2016-10-28
  A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects
• CLINICAL_TRIALS study record update · 2016-10-27
  CHANGE.A Randomized Clinical Trial of Health Promoting Programme Versus Standard Treatment for Patients With Schizophrenia
• CLINICAL_TRIALS study record update · 2016-10-27
  A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia
• CLINICAL_TRIALS study record update · 2016-10-26
  Effect of Repetitive Transcranial Magnetic Stimulation (RTMS) on Resting State Brain Activity in Schizophrenia
• CLINICAL_TRIALS study record update · 2016-10-26
  Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes
• CLINICAL_TRIALS study record update · 2016-10-26
  Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
• CLINICAL_TRIALS study record update · 2016-10-25
  A Randomized Clinical Trial of the Effect of Five-years Versus Two-years Specialized Assertive Intervention for First Episode Psychosis - the OPUS II Trial
• CLINICAL_TRIALS study record update · 2016-10-18
  A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation
• CLINICAL_TRIALS study record update · 2016-10-14
  A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.
• CLINICAL_TRIALS study record update · 2016-10-13
  Antipsychotic Discontinuation in High-risk Subjects
• CLINICAL_TRIALS study record update · 2016-10-13
  A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia